Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.55
- Piotroski Score 2.00
- Grade Speculative Buy
- Symbol (IPA)
- Company ImmunoPrecise Antibodies Ltd.
- Price $0.67
- Changes Percentage (3.24%)
- Change $0.02
- Day Low $0.62
- Day High $0.68
- Year High $2.60
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 09/16/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.42
- Trailing P/E Ratio -2.36
- Forward P/E Ratio -2.36
- P/E Growth -2.36
- Net Income $-27,177,000
Income Statement
Quarterly
Annual
Latest News of IPA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Dua Lipa's all-night party at Glastonbury 2024
Pop singer Dua Lipa fulfilled her dream of performing on the main stage at the Glastonbury Festival. Born in London to Kosovo refugee parents, Lipa's journey to stardom culminated in a triumphant head...
By CBS News | 12 hours ago -
How Dua Lipa manifested her Glastonbury headlining dream, down to the day
Dua Lipa's rise to stardom from small gigs to headlining Glastonbury was a dream come true. Her journey reflects hard work and determination, defying odds to become a Grammy-winning artist....
By CBS News | 12 hours ago -
Trump's historic Abraham Accords would be bolstered with military 'exchange program' under bipartisan bill
Senators Ernst and Rosen are introducing the LINK Act to strengthen U.S. partnerships in the Middle East on the fourth anniversary of the Abraham Accords. The bill aims to enhance military cooperation...
By Fox News | 20 hours ago
